Yujuan Zhang, MD
Pediatric Rheumatology · Boston
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Zhang’s office at (617) 636-5071 to ask if they take your plan before you enroll.
Medicaid work
$29,581 in 2024
Medicaid paid $29,581 for 381 billed services this clinician did in 2024, up to 31 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 280 | $27,842 |
| Prolonged outpatient evaluation and management service(s) time with or without direct patient contact beyond the required time of the primary service when the primary service level has been selected using total time, each 15 minutes of total time (List separately in addition to the code of the outpatient Evaluation and Management service) | 101 | $1,739 |
| 2024 | 381 | 2 | 31 | $29,581 |
| 2023 | 378 | 2 | 31 | $27,355 |
| 2022 | 281 | 2 | 25 | $24,838 |
| 2021 | 195 | 3 | 26 | $17,028 |
| 2020 | 113 | 1 | 16 | $8,601 |
| 2019 | 189 | 1 | 24 | $13,192 |
| 2018 | 71 | 1 | 17 | $5,033 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 303 | $26,124 |
| Prolonged outpatient evaluation and management service(s) time with or without direct patient contact beyond the required time of the primary service when the primary service level has been selected using total time, each 15 minutes of total time (List separately in addition to the code of the outpatient Evaluation and Management service) | 75 | $1,232 |
2022
| Long return visit (40+ min) | 253 | $23,711 |
| Prolonged outpatient evaluation and management service(s) time with or without direct patient contact beyond the required time of the primary service when the primary service level has been selected using total time, each 15 minutes of total time (List separately in addition to the code of the outpatient Evaluation and Management service) | 28 | $1,127 |
2021
| Long return visit (40+ min) | 169 | $16,680 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99205, 99215, 99483 for office or other outpatient evaluation and management services) (do not report g2212 on the same date of service as 99358, 99359, 99415, 99416). (do not report g2212 for any time unit less than 15 minutes) | 13 | $184 |
| Prolonged outpatient evaluation and management service(s) time with or without direct patient contact beyond the required time of the primary service when the primary service level has been selected using total time, each 15 minutes of total time (List separately in addition to the code of the outpatient Evaluation and Management service) | 13 | $164 |
2020
| Return visit (30+ min) | 113 | $8,601 |
2019
| Return visit (30+ min) | 189 | $13,192 |
2018
| Return visit (30+ min) | 71 | $5,033 |
Drugs they prescribed that Part D paid
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their 14 Part D prescriptions in 2023. Too few prescriptions to judge: with under about 50 a year, a handful of patients can swing this share.
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Year by year
| 2023 | 14 | None | 0% (0) | 0% | $179 |
| 2022 | 26 | None | 0% (0) | 62% | $152,870 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2022: 1 drug
| Remicade | 11 | $152,530 | $13,866 |
Money from drug and device companies
$130 in 2025
| 2025 | 3 | 3 | None | $130 |
| 2024 | 1 | 1 | None | $30 |
| 2023 | 1 | 1 | None | $30 |
| 2020 | 1 | 1 | None | $15 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Tempus AI | Xt Cdx | $75 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Hyqvia | $31 | 1 payment
|
| Pfizer | Xeljanz | $24 | 1 payment
|
See all 3 published payments
| Tempus AI | Meals · 2025-12-01 | Xt Cdx | $75 |
| Pfizer | Meals · 2025-03-19 | Xeljanz | $24 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-01-22 | Hyqvia | $31 |
See earlier years (2024, 2023, 2020)
2024: $30
| Takeda Pharmaceuticals U.S.A. | Hyqvia | $30 | 1 payment
|
2023: $30
| Takeda Pharmaceuticals U.S.A. | Hyqvia | $30 | 1 payment
|
2020: $15
| Amgen | Kyprolis | $15 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| PFIZER INC. · Efficacy Safety and Tolerability of Tofacitinib for Treatment of Polyarticular Course Juvenile Idiopathic Arthritis Jia in Children and Adolescent Subjects · 2020 | Their institution | $5,979 |
| PFIZER INC. · A Longterm Openlabel Followup Study of Tofacitinib for Treatment of Juvenile Idiopathic Arthritis Jia · 2024 | Their institution | $4,500 |
| PFIZER INC. · A Longterm Openlabel Followup Study of Tofacitinib for Treatment of Juvenile Idiopathic Arthritis Jia · 2019 | Their institution | $3,479 |
| PFIZER INC. · A Longterm Openlabel Followup Study of Tofacitinib for Treatment of Juvenile Idiopathic Arthritis Jia · 2020 | Their institution | $2,851 |
| PFIZER INC. · A Longterm Openlabel Followup Study of Tofacitinib for Treatment of Juvenile Idiopathic Arthritis Jia · 2021 | Their institution | $2,677 |
Professional record
- NPI
- 1629388467
- Licence
- MA 260838
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2080P0216X (2080P0216X)
- Mailing address
- 800 Washington St, Boston, MA, 02111
- NPI first listed
- 2010-10-14
- NPI last updated
- 2022-07-21
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 700 Welch Rd, Palo Alto, CA, 94304